Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status

Bong Kyung Shin, Youngseok Lee, Jung Bok Lee, Han Kyeom Kim, Jae Bok Lee, Su Jin Cho, Aeree Kim

Research output: Contribution to journalArticle

15 Citations (Scopus)


To evaluate the clinical significance of gene expression-based classification and define the characteristic features of the new basal-like subtype, invasive breast carcinomas were divided into ER, HER2, basal-like and null subtypes by immunohistochemical analysis. A total of 401 invasive breast carcinomas were submitted to tissue microarray and stained with ER, HER2, EGFR, c-KIT and cytokeratin (CK) 5/ 6. The basal-like tumors, defined as positive for one or more basal markers but negative for both ER and HER2, comprised 18.5%. They were larger (p=0.041), showed higher grade (p<0.001), and more frequently expressed p53 (p=0.003). Expression of the basal marker itself showed negative prognostic effect, particularly in node-positive group. Even ER-positive patients had far shorter disease-free survival (DFS) when the tumor coexpressed one or more basal marker (p<0.001). Discrimination of basal-like subtype or tumors positive for basal markers may be clinically significant also in the treatment and prognosis of breast carcinomas.

Original languageEnglish
Pages (from-to)617-625
Number of pages9
JournalOncology reports
Issue number3
Publication statusPublished - 2008 Mar 1



  • Basal
  • Breast carcinoma
  • Gene expression profile
  • Immunohistochemistry

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this